Maximizing Bioavailability and Commercial Success with Softgels

This session will explore the critical role of bioavailability in a drug’s success and how softgel technology can be a strategic solution for commercial longevity. Dr. Peter Surman, Dr. Brett Wagner, and Chris Cuthbertson will look at how a molecule’s market potential is often limited not by its efficacy but by its poor delivery and absorption. They will explain the scientific challenges of bioavailability, such as poor solubility and stability, and how these issues can lead to increased R&D costs, clinical trial failures, and lost market share.

Using case studies they will demonstrate how strategic formulation can overcome significant challenges, such as a drug’s food effect or very low bioavailability. Finally, they will share how early-stage molecule characterization and a partnership with a company like Douglas can be crucial for navigating the complex pathway from candidate selection to market, ultimately helping clients accelerate their drug’s journey to patients and achieve market leadership.

Speakers:

• Dr. Peter Surman – Chief Scientific Officer, Douglas CDMO
• Dr. Brett Wagner – R&D Evaluation Manager, Douglas CDMO
• Chris Cuthbertson – Program Manager for Pharmaceutical Development, Douglas CDMO